Tufton Capital Management buys $10,931,469 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Tufton Capital Management scooped up 169 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 194,718 shares of Merck & Co. which is valued at $10,931,469.Merck & Co. makes up approximately 2.71% of Tufton Capital Management’s portfolio.

Merck & Co. opened for trading at $56.11 and hit $56.83 on the upside on Monday, eventually ending the session at $56.51, with a gain of 0.66% or 0.37 points. The heightened volatility saw the trading volume jump to 77,94,197 shares. Company has a market cap of $156,830 M.

Other Hedge Funds, Including , Heritage Investors Management Corp reduced its stake in MRK by selling 3,462 shares or 1.44% in the most recent quarter. The Hedge Fund company now holds 237,690 shares of MRK which is valued at $13,343,917. Merck & Co. makes up approx 1.01% of Heritage Investors Management Corp’s portfolio.Integrated Investment Consultants boosted its stake in MRK in the latest quarter, The investment management firm added 61 additional shares and now holds a total of 31,386 shares of Merck & Co. which is valued at $1,762,010. Merck & Co. makes up approx 1.00% of Integrated Investment Consultants’s portfolio.Dnb Asset Management As reduced its stake in MRK by selling 123,900 shares or 21.79% in the most recent quarter. The Hedge Fund company now holds 444,671 shares of MRK which is valued at $24,963,830. Merck & Co. makes up approx 0.51% of Dnb Asset Management As’s portfolio.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.